For instance, frequent mutations in TP53, PIK3CA, and EGFR—well-characterized drivers of oral cancer—can be detected by NGS in biofluids [145], providing actionable insights into tumor biology and potential resistance mechanisms to targeted therapies, such as cetuximab. Here, TP53 is linked to neoplasm.